Savings and support for your patients with CF

Chiesi CareDirect® is here to help your patients start, stay, and save on BRONCHITOL® (mannitol) inhalation powder

$0 Copay Assistance

Eligible patients pay as little as $0 for their prescription with copay assistance, automatically applied when a prescription is sent to an in-network specialty pharmacy*

Please see the list of available specialty pharmacies.

Chiesi CareDirect offers additional support services, including:

Benefits Investigations

Benefits investigations

Savings Card Icon

Financial assistance

Chat Bubbles

One-on-one support

  • Patient assistance programs may help qualified patients who are uninsured or underinsured afford their medication
  • Case Advocates deliver 1-on-1 support 7 days a week from 9 am–6 pm EST
  • QuickStart helps new, eligible patients who have passed a BRONCHITOL Tolerance Test get a free, 7-day supply of BRONCHITOL

Restrictions apply. Please see full Terms and Conditions below.

Enroll your eligible patients today so they can take advantage of these support resources

Two options to get your patients started with Chiesi CareDirect:

Fax the completed form to 1-866-410-6241 or email it to chiesicaredirect@caremetx.com.

These downloadable guides can be used
to help you obtain a BRONCHITOL
prescription for your patient:

Contact Chiesi CareDirect

Connect Icon

1-888-865-1222 toll-free,
Monday–Friday from am–6 pm EST

chiesicaredirect@caremetx.com
Shirt, fruit, thumb drive, tickets, lip balm, baseball capWatch and billfold

Chiesi CareDirect Terms and Conditions

BRONCHITOL (mannitol) inhalation powder $0 Copay Assistance Program is available to patients with commercial insurance. Patients pay as little as $0 out-of-pocket costs toward their prescription up to a monthly maximum of $860. To obtain this benefit, patients must be enrolled in Chiesi CareDirect and utilize one of the network specialty pharmacies. Upon enrollment, the offer is valid for 12 months of copay assistance. Patients with primary enrollment in government-funded plans are not eligible for copay assistance.

Patient Assistance Program (PAP) eligibility requirements are available for qualified patients who are uninsured or underinsured and cannot afford their medication.

  • Legal US resident
  • Uninsured
  • Underinsured:
    • Commercially insured patients without prescription coverage are eligible
    • Commercially insured patients with no plan coverage for product are eligible
    • Commercially insured patients appealing plan determination are eligible (during the appeal process)
  • Patients with a government funded plan are not eligible for PAP (Medicare Part D, Medicaid, etc)

QuickStart program offers new, eligible commercial patients who pass the BRONCHITOL Tolerance Test a free supply of BRONCHITOL. Patient must be new to BRONCHITOL and must have commercial insurance (not be participating in any government-funded programs).

Important Safety
Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

Indication

BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.

Please see Full Prescribing Information.